Physician
Southeastern Medical Oncology Center
Southeastern Medical Oncology Center was paid $3.91M by Medicaid between Jan 2018 and Dec 2024, across 41 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 22% of everything it billed.
33Billing provider infoSOUTHEASTERN MEDICAL ONCOLOGY CENTER
GOLDSBORO, NC 27534
GOLDSBORO, NC 27534
33aNPI1306828678assigned 11/14/2005
33bProvider typeHematology & Oncology Physician
28Total paid$3.91M
24GClaims175,791
24DCodes billed41
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Hematology & Oncology Physician providers in North Carolina
Rank by total paid#1 of 46
Median peer was paid$36K
This provider vs. median110×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 16,583 | $290K | |
| 2019 | 19,986 | $446K | |
| 2020 | 18,032 | $361K | |
| 2021 | 22,594 | $489K | |
| 2022 | 33,163 | $669K | |
| 2023 | 33,661 | $922K | |
| 2024incomplete | 31,772 | $732K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 22% | 16,512 | 13,698 | $840K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 13% | 8,952 | 5,908 | $509K |
| J1437 | Injection, ferric derisomaltose, 10 mg | 12% | 231 | 183 | $461K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 10% | 727 | 574 | $397K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 8.8% | 10,322 | 9,002 | $345K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 8.1% | 4,796 | 3,552 | $316K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 5.2% | 43,513 | 32,134 | $202K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 4.1% | 5,712 | 4,235 | $160K |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 3.4% | 729 | 520 | $132K |
| 96367 | 3.0% | 5,600 | 3,651 | $117K | |
| 80053 | Comprehensive metabolic panel | 2.7% | 21,511 | 16,241 | $104K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.2% | 9,459 | 7,220 | $84K |
29 more codes
| J2469 | Injection, palonosetron hcl, 25 mcg | 1.2% | 643 | $48K |
| 99204 | Doctor's office visit, new patient (more involved) | 1.2% | 486 | $48K |
| 36415 | Collection of venous blood by venipuncture | <1% | 25,441 | $33K |
| 82728 | <1% | 3,411 | $26K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,380 | $20K |
| 83550 | <1% | 1,771 | $10K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 186 | $9K |
| 96417 | <1% | 211 | $9K | |
| 83540 | <1% | 1,772 | $7K | |
| 83735 | <1% | 1,632 | $6K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 735 | $6K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 72 | $5K |
| 96415 | <1% | 192 | $4K | |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 36 | $3K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 185 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,744 | $2K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 54 | $1K |
| 99443 | <1% | 15 | $1K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 4,670 | $994.32 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 296 | $731.36 |
| 90674 | <1% | 104 | $394.52 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 28 | $291.72 |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 15 | $205.01 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 167 | $64.68 |
| 81001 | <1% | 12 | $36.99 | |
| J3490 | Unclassified drugs | <1% | 39 | $0.60 |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 16 | $0.03 |
| J9999 | Not otherwise classified, antineoplastic drugs | 0% | 360 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 54 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHOYT, TERESA (BUSINESS MANAGER)